Primary objective of the trial is to demonstrate non-inferior efficacy of six cycles of
BrECADD compared to six cycles of escalated BEACOPP, each followed by radiotherapy to
PET-positive residual lesions ≥2.5 cm, in terms of progression free survival (efficacy
objective).
If non-inferior efficacy can be shown, the co-primary objective is to further demonstrate
reduced toxicity of the BrECADD treatment compared to the escalated BEACOPP treatment
measured by treatment related morbidity (TRMorbidity objective).